-
Scientists Discover Drug Combination That Targets BAP1-Deficient Mesothelioma
Scientists have discovered a promising drug combination that shrinks tumors and prolongs survival in patients with mesothelioma and other cancers that contain BAP1 mutations. The treatment approach takes advantage of the fact that the genetic change makes the asbestos-related cancer’s deadly tumors less aggressive and more treatable than those without the mutation.
-
Study Shows Peritoneal Mesothelioma Microenvironment Creates Poor Immunotherapy Response
Australian researchers have discovered that peritoneal mesothelioma develops in an immune-suppressive tumor microenvironment that makes it resistant to checkpoint immunotherapy. These findings explain the significant difference between pleural mesothelioma and peritoneal mesothelioma patients observed in clinical trials.
-
Memorial Sloan Kettering Study Reports Increase in Mesothelioma in Younger, Female Patients
A just-released study from researchers at New York’s Memorial Sloan Kettering Cancer Center has revealed an alarming trend of diagnoses in patients under age 50, particularly among younger women with no self-reported history of asbestos exposure. The study’s authors urge physicians to familiarize themselves with the symptoms of the rare form of cancer and consider
-
Study Confirms Importance of Low-Dose CT Lung Screening for Mesothelioma and Other Cancers
A recent study of low-dose CT lung cancer screening results reinforces the technology’s importance for screening those at risk of mesothelioma. Researchers from Brown University found that the protocol has detected “significant incidental findings” linked to increased risk of extrapulmonary cancer diagnoses—including cancers affecting the pleura.
-
1977 Talc Safety Article Retracted After Author is Linked to Johnson & Johnson
In a move that is sure to have significant implications for mesothelioma and ovarian cancer litigation, one of the world’s most prestigious medical journals has retracted a 49-year-old unsigned commentary on cosmetic talc safety. The Lancet announced the action after the article’s author was discovered to be a paid Johnson & Johnson consultant.
-
Jury Awards $33.4 Million to Mesothelioma Victim Sickened by Lighting Equipment
A Los Angeles County Superior Court jury has awarded over $33 million in non-economic damages to an 80-year-old U.S. Army veteran who blamed exposure to asbestos-containing theatrical lighting equipment for his diagnosis with pleural mesothelioma. The jury found the company 100% liable and guilty of malice.
-
Jury Orders Shipyard to Pay $6.6 Million to Mesothelioma Victim’s Survivors
In Louisiana, an Orleans Parish jury has awarded $6.625 million in damages to the family of a former Avondale Shipyards clerk who died from mesothelioma. The group took just 80 minutes to find that Ronald Marcella’s fatal illness was caused by exposure he experienced at the shipyard from 1962 to 1964.
-
Japan Approves Workers’ Compensation for Mesothelioma Death of Cosmetics Salesclerk
In a case highlighting the global problem of asbestos contamination in talc products, the Sendai Labor Standards Inspection Office in Japan has approved workers’ compensation following the mesothelioma death of a 68-year-old former Shiseido Co. salesclerk. The group ruled that she likely developed the rare form of cancer from having been exposed to contaminated cosmetics
-
Talc Company Fails in Attempt to Dismiss Mesothelioma Lawsuit
After Stuart Linde died of mesothelioma in 2023, his estate sued Bristol Myers Squibb (BMS), blaming the company’s Ammens talc powder for his fatal illness. While the pharmaceutical giant filed a petition to have the case dismissed, the New York Supreme Court denied its motion for summary judgment, finding that genuine issues of fact need
-
Harvard’s Post-Surgery Blood Clot Study Could Save Mesothelioma Patients’ Lives
Pleural mesothelioma surgery presents several risks, including a much higher risk of blood clots than in patients undergoing other surgeries. In a recent study, researchers from Harvard University identified biomarkers that could predict which mesothelioma patients face the highest risk. This discovery could reduce the current 11% mortality rate from post-operative venous thromboembolism (VTE) that
-
Kentucky Court Rules Workers’ Comp Doesn’t Bar Secondary Mesothelioma Claims
A groundbreaking ruling by the Kentucky Supreme Court made all the difference for the family of a woman who died of mesothelioma in 2017. Following nearly ten years of litigation, the court ruled that the state’s’ workers’ compensation exclusivity rule doesn’t prevent negligence and product liability claims stemming from “take-home” asbestos exposure.
-
Researchers Use Advanced MRI Technique to Identify Early-Stage Mesothelioma
In a recently published article, researchers from the University of Glasgow and Queen Elizabeth University Hospital in Glasgow report that they successfully used an advanced MRI scanning technique to detect early-stage mesothelioma tumors. The ability to find tumors too small to spot easily with standard imaging offers hope for earlier diagnosis, when the asbestos-related cancer
-
$16 Million Johnson & Johnson Mesothelioma Award Stands
The family of an 88-year-old woman who died of mesothelioma received a mix decsion regarding the $966 million a jury had ordered Johnson & Johnson to pay them. Though a Los Angeles County Superior Court judge allowed the $16 million in compensatory damages verdict to stand, she eliminated the jury’s ordered $950 million in punitive
-
Supreme Court Denies Volkswagen Appeal in California Mesothelioma Case
The U.S. Supreme Court declined to hear Volkswagen AG’s petition challenging California courts’ jurisdiction over a mesothelioma lawsuit. The original case was filed by the family of Raul Hernandez, who died from the rare, asbestos-related cancer after working as a mechanic at Volkswagen dealerships from 1969 to 1976.
-
Study Shows Impact of Molecular Alterations on Mesothelioma Survival
A large, multi-institutional analysis using the International Association for the Study of Lung Cancer (IASLC) staging database shows that molecular alterations in mesothelioma cells significantly influence survival. Tracking these changes may also improve the ability to predict survival beyond what is currently being used for these assessments.
-
Mesothelioma Research Links Cellular Modification to Tumor Growth
Mesothelioma researchers have discovered a critical connection between disrupted cellular growth controls and a biochemical process called O-GlcNAcylation. The finding offers scientists a new biological target within mesothelioma’s tumors, and could revolutionize treatment for the aggressive asbestos-related cancer.
-
Proton Beam Therapy Trial Offers Hope for Better Mesothelioma Survival Outcomes
Mesothelioma is an aggressive asbestos-related cancer that currently has no cure, but researchers in the United Kingdom say that a groundbreaking clinical trial is using proton beam therapy to increase two-year survival rates from 30% to 50%. To date, the results are offering what’s being called “realistic hope” to patients.
-
Mesothelioma Trial Against Pep Boys Settles
A lawsuit filed against Pep Boys by the husband of an 85-year-old mesothelioma victim was settled for an undisclosed amount shortly after evidence began being presented to the jury. Alex Munoz blamed his wife’s fatal cancer on her having washed her son’s asbestos-contaminated work clothes after he performed brake work at the automotive retailer in
-
Court Upholds $9 Million Shotgun Shell Mesothelioma Verdict
In July 2025, a Delaware jury ordered two shotgun shell suppliers to pay $9 million in damages to the family of mesothelioma victim Eugene Schoepke. Though the companies filed post-trial motions challenging this decision, the Delaware Superior Court denied their request, ruling that sufficient evidence had been provided to establish that the hunter’s fatal cancer
-
Judge Awards $24.6 Million Mesothelioma Judgment After Company Defaults
A California Superior Court judge has ordered former Gold Bond powder owner Martin Himmel, Inc. to pay a $24.6 million default judgment to a mesothelioma victim who blames the company’s talc product for his illness. The judgment came after the company failed to defend itself against the claim.
